Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals (MXC) sees the Israeli Ministry of Health grant approval for a global dosing study for treating the effects of COVID-19 using CimetrA
- The company will recruit 240 patients into the study, with dosing sites in Israel, South Africa, Russia and the US
- Spanning over 28 days, the company will observe the effects of the treatment, which will then be submitted to health authorities
- MGC Pharma says the results of the dosing study will enable it to determine the most effective dosage of CimetrA for treating symptoms of COVID-19, which will provide evidence of the drug’s efficacy globally
- MGC Pharmaceuticals last traded at 4.8 cents
MGC Pharmaceuticals (MXC) has seen the Israeli Ministry of Health grant approval for a global dosing study for treating the effects of COVID-19.
The study will treat patients infected with COVID-19 using the company’s lead drug candidate, CimetrA.
The study is set to incorporate key parameters, including determining the most effective dosage of the treatment, a full safety profile, and a pharmacokinetic profile to outline the administrative process of approval for use and sale.
The company will recruit 240 patients into the study, with dosing sites in Israel, South Africa, Russia, and the US.
Spanning over 28 days, the company will observe the effects of the treatment, which will then be submitted to health authorities.
MGC Pharma said the results of the dosing study will enable it to determine the most effective dosage of CimetrA for treating symptoms of COVID-19. These will then be used to provide additional evidence of the drug’s efficacy globally.
“This latest dosage study is the latest step as we move closer to being in a position to apply for marketing authorisation for CimetrA in territories across the globe,” Managing Director and Co-founder Roby Zomer said.
“We believe that CimetrA will prove to be a vitally important drug in the treatment of COVID-19 going forward, and look forward to sharing the results of the study in due course, along with further steps towards providing COVID-19 patients and governments across the world a cost effective treatment to fast track patient recovery and minimise the massive cost burden of long term hospitalisation.”
MGC Pharmaceuticals last traded at 4.8 cents at 2:27 pm AEDT.
